INBX logo

INHIBRX BIOSCIENCES INC

INBXNASDAQ
🏆 #2198 by market capUS Equity
$716.09▲ $42.68 (+5.96%)
Simulated price
🔔
Track INBX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 6.0%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$1.49B
Small Cap
📈Revenue Growth (YoY)
+550.0%
High Growth
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
64
Fair
No chart data available for INBX.

Trading Snapshot

Day Range
$710.67 – $722.51
52-Week Range
$28.16 – $155.29
Volume
$5.03B
Avg Volume
$5.64B
Shares Outstanding
14.7M
Next Earnings
Nov 23, 2026

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$315,270
P/E Ratio
-11.5
P/S Ratio
0.0x
EPS (TTM)
$-8.82
Dividend Yield
0.00%

Why Investors Own INBX

  • ✓High-growth profile — revenue up +11.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 56% gross margin and 24% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

INBX logo

INHIBRX BIOSCIENCES INC

INBX
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$1M▲ +6.9% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
55.6%▼ −0.5% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$457,600▲ +6.9% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$314,600▲ +6.9% YoY
StockOtter · stockotter.space

About INHIBRX BIOSCIENCES INC

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Price Target

ⓘ
Average Target
$754.53
▲ +5.4% Upside
High Target$827.88
Low Target$630.62
Based on 33 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

INHIBRX BIOSCIENCES INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift INBX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

INHIBRX BIOSCIENCES INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.